CNS Update: The Effect of Pregabalin on Chemokines in Patients with Neuropathic Pain |
News and Updates
eMediNexus Coverage from: 
CNS Update: The Effect of Pregabalin on Chemokines in Patients with Neuropathic Pain
eMediNexuS,  23 June 2022
Coronavirus Live Count Map India

remove_red_eye 1405 Views
COVID-19 Vaccine Updates


#Neurology

0 Read Comments                

Pregabalins effect on chemokines and its clinical effectiveness in 40 patients with neuropathic pain was examined in a recent study. The enrolled subjects were randomly divided into observation and control groups.

The observation group and the control group received treatment with pregabalin and gabapentin respectively. Extracted cerebrospinal fluid from the patients was subjected to detection of concentration levels of C-X3-C motif chemokine ligand 1, C-X-C motif chemokine ligand 1, C-X-C motif chemokine ligand 8 and C-C motif chemokine ligand 2. The concentration levels, the adverse drug reactions and clinical effects were compared between the groups.

Treatment showed a reduction in the concentration levels of cerebrospinal fluid chemokines C-X3-C motif chemokine ligand 1, C-X-C motif chemokine ligand 1, C-X-C motif chemokine ligand 8 and C-C motif chemokine ligand 2 in both groups. However, this change was more pronounced in the observation group along with a greater clinical remission rate than in the control group.

 

Thus it was inferred that pregabalin treatment reduces the chemokines in cerebrospinal fluid and relieves the pain of patients with neuropathic pain.

To comment on this article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now